Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors

Journal of Neuro-Oncology

Volumn 104, Issue 3, 2011, Pages 779-787

  Kawaguchi, Tomohiro ^a   Kumabe, Toshihiro ^a   Kanamori, Masayuki ^a   Saito, Ryuta ^a   Yamashita, Yoji ^a   Sonoda, Yukihiko ^a   Watanabe, Mika ^b   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Alpha fetoprotein; Human chorionic gonadotropin; Neoadjuvant chemotherapy; Non germinomatous germ cell tumors; Outcome

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; BRAIN CANCER; BRAIN RADIATION; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHORIOCARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GERM CELL TUMOR; GONADOTROPIN BLOOD LEVEL; HUMAN; HYDROCEPHALUS; INTRACRANIAL NON GERMINOMATOUS GERM CELL TUMOR; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; YOLK SAC TUMOR;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHORIONIC GONADOTROPIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOADJUVANT THERAPY; PROGNOSIS; SALVAGE THERAPY; SPINAL CORD; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052641538     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0544-2     Document Type: Article

References (36)

1. Committee of Brain Tumor Registry of Japan 2003 Report of brain tumor registry of Japan (1969-1996) Neurol Med Chir (Tokyo) 43 Suppl 1 111 10.2176/nmc.43.S1
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon
3. CR Kersh WC Constable DR Eisert CA Spaulding SS Hahn JM Jenrette III, et al. 1988 Primary central nervous system germ cell tumors: effect of histologic confirmation on radiotherapy Cancer 61 2148 2152 3365647 10.1002/1097- 0142(19880601)61:11<2148::AID-CNCR2820611103>3.0.CO;2-Q 1:STN:280:DyaL1c3htVWrtg%3D%3D
4. H Shirato M Nishio Y Sawamura M Myojin T Kitahara T Nishioka, et al. 1997 Analysis of long-term treatment of intracranial germinoma Int J Radiat Oncol Biol Phys 37 511 515 9112446 10.1016/S0360-3016(96)00607-4 1:STN:280: DyaK2s3ms1OhsQ%3D%3D (Pubitemid 27175303)
5. MT Jennings R Gelman F Hochberg 1985 Intracranial germ-cell tumors: natural history and pathogenesis J Neurosurg 63 155 167 2991485 10.3171/jns.1985.63.2.0155 1:STN:280:DyaL2M3mtlyhsQ%3D%3D (Pubitemid 15246078)
6. M Kanamori T Kumabe R Saito Y Yamashita Y Sonoda H Ariga, et al. 2009 Optimal treatment strategy for intracranial germ cell tumors: a single institution analysis J Neurosurg Pediatr 4 506 514 19951035 10.3171/2009.7. PEDS08288
7. M Matsutani Y Ushio H Abe J Yamashita S Shibui T Fujimaki The Japanese Pediatric Brain Tumor Study Group, et al. 1998 Combined chemotherapy and radiation therapy for central nervous system germ cell tumors: preliminary results of a Phase II study of the Japanese Pediatric Brain Tumor Study Group Neurosurg Focus 5 1 e7 17140188 10.3171/foc.1998.5.1.10
8. K Ogawa T Toita K Nakamura T Uno H Onishi J Itami, et al. 2003 Treatment and prognosis of patients with intracranial nongerminomatous malignant germ cell tumors: a multiinstitutional retrospective analysis of 41 patients Cancer 98 369 376 12872359 10.1002/cncr.11495 (Pubitemid 36828464)
9. M Matsutani Japanese Pediatric Brain Tumor Study Group 2001 Combined chemotherapy and radiation therapy for CNS germ cell tumors. The Japanese experience J Neurooncol 54 311 316 11767296 10.1023/A:1012743707883 1:STN:280:DC%2BD38%2FktFWnsQ%3D%3D
10. M Kochi Y Itoyama S Shiraishi I Kitamura T Marubayashi Y Ushio 2003 Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma J Neurosurg 99 106 114 12854751 10.3171/jns.2003.99.1.0106
11. Y Ushio M Kochi J Kuratsu Y Itoyama T Marubayashi 1999 Preliminary observations for a new treatment in children with primary intracranial yolk sac tumor or embryonal carcinoma. Report of five cases J Neurosurg 90 133 137 10413166 10.3171/jns.1999.90.1.0133 1:STN:280:DyaK1MzjvFGisw%3D%3D (Pubitemid 29024750)
12. J Shinoda N Sakai H Yano T Hattori A Okuyama H Sakaguchi 2004 Prognostic factors and therapeutic problems of primary intracranial choriocarcinoma/germ- cell tumors with high levels of HCG J Neurooncol 66 225 240 15015791 10.1023/B:NEON.0000013499.74404.81 (Pubitemid 38258379)
13. O Arrieta RM Michel Ortega J Angeles-Sánchez C Villarreal-Garza A Avilés-Salas JG Chanona-Vilchis, et al. 2009 Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors J Exp Clin Cancer Res 28 120 19709439 10.1186/1756-9966-28-120
14. AP Doherty M Bower TJ Christmas 1997 The role of tumour markers in the diagnosis and treatment of testicular germ cell cancers Br J Urol 79 247 252 9052477 1:CAS:528:DyaK2sXhsFeqt7s%3D
15. PT Scardino HD Cox TA Waldmann KR Mcintire B Mittenmeyer N Javadpour 1977 The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis J Urol 118 994 999 72833 1:CAS:528:DyaE1cXnt1Krsg%3D%3D (Pubitemid 8261174)
16. Calaminus G, Patte C (2005) Germ cell tumors in children and adolescents. In: Agarwal BR, Perilongo G, Rogers P, Strahlendorf C, Eden OB (eds) SIOP education book 2005. SIOP, Vancouver, Canada, pp 109-116
17. T Nakamura M Kanamori Y Sonoda M Watanabe T Kumabe T Tominaga 2009 Primary yolk sac tumor in the cerebellar vermis. Case report No Shinkei Geka 37 173 177 19227159
18. Y Sonoda T Kumabe S Sugiyama M Kanamori Y Yamashita R Saito, et al. 2008 Germ cell tumors in the basal ganglia: problems of early diagnosis and treatment J Neurosurg Pediatr 2 118 124 18671616 10.3171/PED/2008/2/8/118
19. M Matsutani K Sano K Takakura T Fujimaki O Nakamura N Funata, et al. 1997 Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases J Neurosurg 86 446 455 9046301 10.3171/jns.1997.86.3.0446 1:STN:280:DyaK2s7pvVantQ%3D%3D (Pubitemid 27097090)
20. C Alapetite C Carrie E Brisse P Thiesse JL Habrand JC Cuilliere, et al. 2001 Patterns of relapse following focal irradiation for intracranial germinoma. Critical review of TGM-TC90-SFOP protocol Med Pediatr Oncol 37 3 249
21. U Göbel DT Schneider G Calaminus H Jürgens HJ Spaar W Sternschulte, et al. 2001 Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the german cooperative protocols MAKEI 83/86 and 89 J Clin Oncol 19 1943 1950 11283126 (Pubitemid 32702538)
22. Calaminus G, Garre ML, Kortmann RD, Mann JR, Göbel U (1998) CNS germ cell tumors in children. Results of the German MAKEI89 protocols and SIOP CNS GCT 93P/96 study In: Jones DP, Appleyard I, Joffe JK, Harnden P (eds) Germ Cell Tumours IV. Springer, London, pp 247-254
23. M Bamberg RD Kortmann G Calaminus G Becker C Meisner D Harms, et al. 1999 Radiation therapy for intracranial germinoma: results of the German cooperative prospective trials MAKEI 83/86/89 J Clin Oncol 17 2585 2592 10561326 1:STN:280:DC%2BD3c%2FjtVSmtw%3D%3D (Pubitemid 29368262)
24. Bower M, Rustin GJ (2000) Serum tumor markers and their role in monitoring germ cell cancers of the testis. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds) Comprehensive textbook of genitourinary oncology, 2nd edn. Lippincott, Philadelphia, p 931
25. PH Lange NJ Vogelzang A Goldman BJ Kennedy EE Fraley 1982 Marker half-life analysis as a prognostic tool in testicular cancer J Urol 128 708 711 6183454 1:STN:280:DyaL3s%2FlvF2msQ%3D%3D (Pubitemid 13236336)
26. RE Wehmann BC Nisula 1981 Metabolic and renal clearance rates of purified human chorionic gonadotropin J Clin Invest 68 184 194 7251859 10.1172/JCI110234 1:CAS:528:DyaL3MXkslCisb0%3D (Pubitemid 11048091)
27. A Gerl R Lamerz C Clemm K Mann R Hartenstein W Wilmanns 1996 Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res 2 1565 1570 9816334 1:STN:280:DyaK1M%2FjsFWrsA%3D%3D (Pubitemid 126447451)
28. M Mazumdar DF Bajorin J Bacik G Higgins RJ Motzer GJ Bosl 2001 Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy J Clin Oncol 19 2534 2541 11331333 1:CAS:528:DC%2BD3MXjvVelu74%3D (Pubitemid 32391225)
29. GJ Bosl MD Head 1994 Serum tumor marker half-life during chemotherapy in patients with germ cell tumors Int J Biol Markers 9 25 28 7519650 1:STN:280:DyaK2czisl2ktg%3D%3D (Pubitemid 24135514)
30. K Fizazi S Culine A Kramar RJ Amato J Bouzy I Chen, et al. 2004 Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis non-seminomatous germ-cell tumors J Clin Oncol 22 3868 3876 15302906 10.1200/JCO.2004.04.008 (Pubitemid 41079867)
31. SB Saxman CR Nichols RS Foster JE Messemer JP Donohue LH Einhorn 1996 The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers J Urol 155 587 589 8558665 10.1016/S0022-5347(01)66457-7 1:STN:280:DyaK287jsVejsA%3D%3D (Pubitemid 26023549)
32. ME Blohm D Vesterling-Hörner G Calaminus U Göbel 1998 Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age Pediatr Hematol Oncol 15 135 142 9592840 10.3109/08880019809167228 1:STN:280: DyaK1c3lsFWqug%3D%3D (Pubitemid 28213543)
33. R de Wit R Sylvester C Tsitsa PH de Mulder DT Sleyfer WW ten Bokkel Huinink, et al. 1997 Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 432 435 9020492 10.1038/bjc.1997.71 (Pubitemid 27051062)
34. MJ Stevens AR Norman DP Dearnaley A Horwich 1995 Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma J Clin Oncol 13 87 92 7528272 1:STN:280:DyaK2M%2Fps12ktw%3D%3D
35. GC Toner NL Geller C Tan J Nisselbaum GJ Bosl 1990 Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors Cancer Res 50 5904 5910 1697503 1:STN:280:DyaK3czmslShtA%3D%3D (Pubitemid 20331398)
36. GC Toner 2004 Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use J Clin Oncol 22 3842 3845 15302908 10.1200/JCO.2004.06.923 (Pubitemid 41079862)